{"protocolSection":{"identificationModule":{"nctId":"NCT06698939","orgStudyIdInfo":{"id":"ORKA-001-111"},"organization":{"fullName":"Oruka Therapeutics, Inc.","class":"INDUSTRY"},"briefTitle":"ORKA-001 in Healthy Volunteers","officialTitle":"Phase 1, First-in-human, Double-Blind, Placebo-Controlled, Single Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics, of ORKA-001 in Healthy Participants","acronym":"ORKA-001-111"},"statusModule":{"statusVerifiedDate":"2025-05","overallStatus":"ACTIVE_NOT_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2024-12-19","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-06","type":"ESTIMATED"},"completionDateStruct":{"date":"2026-06","type":"ESTIMATED"},"studyFirstSubmitDate":"2024-11-13","studyFirstSubmitQcDate":"2024-11-18","studyFirstPostDateStruct":{"date":"2024-11-21","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-05-15","lastUpdatePostDateStruct":{"date":"2025-05-18","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Oruka Therapeutics, Inc.","class":"INDUSTRY"}},"oversightModule":{"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This is a Phase 1, First-in-human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ORKA-001 in Healthy Participants.","detailedDescription":"This is a single center, phase 1, double-blind, placebo-controlled, randomized, first-in-human (FIH), single ascending dose study evaluating the safety, tolerability, and pharmacokinetics (PK) of ORKA-001 in healthy volunteers. The study will enroll approximately 24 healthy volunteers. The ORKA-001 dose will be administered by a subcutaneous injection."},"conditionsModule":{"conditions":["Healthy Volunteers"],"keywords":["ORKA-001","Phase 1"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"OTHER","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":24,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"ORKA-001","type":"EXPERIMENTAL","description":"Participants will receive subcutaneous injection of ORKA-001 at either 300 mg, 600 mg or 1200 mg.","interventionNames":["Drug: ORKA-001"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"Participants will receive a subcutaneous injection of placebo comparator.","interventionNames":["Other: Placebo"]}],"interventions":[{"type":"DRUG","name":"ORKA-001","description":"ORKA-001 is supplied as sterile solution to be administered by SC injection","armGroupLabels":["ORKA-001"]},{"type":"OTHER","name":"Placebo","description":"Placebo solution to be administered at a matching volume by SC injection","armGroupLabels":["Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number and frequency of Treatment-Emergent Adverse Events [Safety and Tolerability]","description":"Incidence of treatment-emergent adverse events (TEAEs) and clinically significant changes from baseline in vital signs, electrocardiograms (ECGs), clinical laboratory parameters, and physical examinations.","timeFrame":"Day 1 through one year"}],"secondaryOutcomes":[{"measure":"Maximum observed serum concentration of ORKA-001","description":"CMax of ORKA-001","timeFrame":"Day 1 through one year"},{"measure":"Time to CMax (TMax) of ORKA-001","description":"TMax of ORKA-001","timeFrame":"Day 1 through one year"},{"measure":"Area Under the Serum Concentration-Time Curve (AUC) of ORKA-001","description":"Area under the curve from the time of dosing to infinity (AUC0-inf)","timeFrame":"Day 1 through one year"},{"measure":"Terminal elimination half-life (T1/2)","description":"T1/2 of ORKA-001","timeFrame":"Day 1 through one year"}]},"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n1. Healthy male or female participants\n2. 18 to 65 years (inclusive) with a body mass index (BMI) 18 to 32 kg/m2\n3. Willing and able to remain at the study site unit for the duration of the confinement period and return for the outpatient visit/s defined in the protocol\n4. Using a highly effective method of contraception from admission through the end of the study.\n5. Willing to abstain from regular, continuous alcohol use or tobacco use as per protocol\n\nKey Exclusion Criteria:\n\n1. Any clinically significant medical condition or finding that, in the Investigator's opinion, is likely to unfavorably alter the risk of study participation, confound study results, or interfere with the study conduct or compliance.\n2. Known history of illicit drug use or drug abuse or harmful alcohol use\n3. Known history of frequent tobacco or vaping use within 2 years prior to Screening\n4. History of severe allergic reactions or hypersensitivity\n5. Actively nursing or lactating\n6. Use of investigational drug therapy within 30 days prior to enrollment\n7. Unable to comply with study requirements or in the opinion of the Investigator should not participate in this study.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Kyle Breitschwerdt","affiliation":"Oruka Therapeutics, Inc.","role":"STUDY_DIRECTOR"},{"name":"Principal Investigator","affiliation":"Oruka Therapeutics Investigative Site","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Oruka Therapeutics Investigative Site","city":"Christchurch","country":"New Zealand","geoPoint":{"lat":-43.53333,"lon":172.63333}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"}},"hasResults":false}